Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Antiinfective agent stubs
GNF6702
Другие языки:

    GNF6702

    Подписчиков: 0, рейтинг: 0
    GNF6702
    GNF6702 structure.png
    Identifiers
    • N-[4-fluoro-3-(6-pyridin-2-yl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)phenyl]-2,4-dimethyl-1,3-oxazole-5-carboxamide
    CAS Number
    PubChem CID
    ChemSpider
    UNII
    ChEBI
    Chemical and physical data
    Formula C22H16FN7O3
    Molar mass 429.406 g·mol−1
    3D model (JSmol)
    • n5ccccc5-c(cn1n4)cnc1nc4-c3cc(ccc3F)NC(=O)c2oc(C)nc2C
    • InChI=1S/C22H16FN7O2/c1-12-19(32-13(2)26-12)21(31)27-15-6-7-17(23)16(9-15)20-28-22-25-10-14(11-30(22)29-20)18-5-3-4-8-24-18/h3-11H,1-2H3,(H,27,31)
    • Key:WXZFCGRYVWYYTG-UHFFFAOYSA-N

    GNF6702 is the name for a broad-spectrum antiprotozoal drug invented by researchers working at the Genomics Institute of the Novartis Research Foundation in 2013, with activity against leishmaniasis, Chagas disease and sleeping sickness. These three diseases are caused by related kinetoplastid parasites, which share similar biology. GNF6702 acts as allosteric proteasome inhibitor which was effective against infection with any of the three protozoal diseases in mice, while having little evident toxicity to mammalian cells.

    See also



    Новое сообщение